Exosens/€EXENS
1D1W1MYTD1Y5YMAX
Capital at risk
About Exosens
Exosens is a high-tech company specializing in the innovation, development, manufacturing, and sale of advanced electro-optical technologies in amplification, detection, and imaging. Its product portfolio includes traveling wave tubes, advanced cameras, neutron and gamma detectors, instrument detectors, and light intensifier tubes, serving sectors such as defense, life sciences, industrial control, and nuclear energy. Founded over 85 years ago, the company rebranded from Photonis Group to Exosens in September 2023 to reflect its expanded technological scope. Headquartered in Mérignac, France, Exosens operates 12 production and R&D sites across Europe and North America, employing over 1,700 individuals. The company's strategic positioning is bolstered by sustained investments in innovation and a series of acquisitions, including Xenics, Proxivision, Telops, and Elmul since December 2022, enhancing its capabilities in detection and imaging technologies. (,)
- Ticker
- €EXENS
- Sector
- Industrials
- Primary listing
- PAR
- Employees
- 2,000
- Headquarters
- Mérignac, France
- Website
- www.exosens.com
Exosens Metrics
BasicAdvanced
€2.8B
91.45
€0.59
0.85
€0.30
0.55%
Price and volume
Market cap
€2.8B
Beta
0.85
52-week high
€72.10
52-week low
€41.00
Average daily volume
62K
Dividend rate
€0.30
Financial strength
Current ratio
2.352
Quick ratio
1.397
Long term debt to equity
0.586
Total debt to equity
0.598
Dividend payout ratio (TTM)
50.43%
Interest coverage (TTM)
8.66%
Profitability
EBITDA (TTM)
104.887
Gross margin (TTM)
60.52%
Net profit margin (TTM)
6.01%
Operating margin (TTM)
17.48%
Effective tax rate (TTM)
23.06%
Revenue per employee (TTM)
€250,000
Management effectiveness
Return on assets (TTM)
6.19%
Return on equity (TTM)
12.71%
Valuation
Price to earnings (TTM)
91.447
Price to revenue (TTM)
5.466
Price to book
6.11
Price to tangible book (TTM)
136.48
Price to free cash flow (TTM)
47.248
Free cash flow yield (TTM)
2.12%
Free cash flow per share (TTM)
1.148
Dividend yield (TTM)
0.55%
Forward dividend yield
0.55%
Growth
Revenue change (TTM)
20.61%
Earnings per share change (TTM)
-45.63%
Bulls say / Bears say
Exosens exceeded its full-year 2025 guidance with revenue up 22.1% to €468.2 million and profit more than doubling, prompting management to raise its mid-term organic revenue and EBITDA growth targets to over 15%, driven by strong Defense & Surveillance demand. (Reuters)
In Q1 2026, Exosens delivered 19.7% revenue growth to €122.6 million and saw adjusted gross profit climb 20.1% to €63.5 million, driven by accelerating demand for night vision and digital imaging solutions, leaving it on track to meet full-year guidance. (Reuters)
Photonis Defense, Exosens’ U.S. subsidiary, won a firm-fixed-price US Army BiNOD contract worth up to US$352.6 million through 2033, marking a major milestone in Exosens’ expansion in the world’s largest night vision market. (Reuters)
Exosens remains heavily reliant on its Defense & Surveillance business, which accounted for 75% of total revenue in 2025, exposing it to shifts in government defense budgets and procurement cycles. (Reuters)
Citi resumed coverage with a “neutral/high risk” rating, citing insufficient valuation upside and the stock’s short trading history despite strong growth metrics, underscoring market skepticism. (Reuters)
The company plans capital expenditures of around 9% of 2026 revenue to triple thermal-camera production capacity, raising execution risk and potential strain on cash flow if market demand slows. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
Upcoming events
No upcoming events
Funds containing Exosens
AllGBPEURUSD
Fund name | Fund size | €EXENS weighting |
|---|---|---|
Wisdomtree Europe Defence£WDEP | £4.2B | 0.66% |
VanEck Defense€DFEN | €2.8B | 0.55% |
Vaneck Defense£DFNG | £2.4B | 0.55% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.13% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.